You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Vasculitis

Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

  • Technology appraisal guidance
  • Reference number: TA308
  • Published:  26 March 2014
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): final appraisal determination document

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): final appraisal determination document Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): final appraisal determination document
24 January 2014
(515.28 Kb 30 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 24 January 2014

Back to top